ABIONYX Pharma and OLON partner to prepare CER-001 for regulatory approval and commercial manufacturing
ABIONYX Pharma and OLON have established a strategic manufacturing partnership to support regulatory preparations and potential commercial production of CER-001.
The agreement covers an integrated manufacturing framework for CER-001, a recombinant apoA-I-based HDL-mimetic biologic, including two validation batches supporting its LCAT deficiency regulatory pathway.
The collaboration also prepares for potential commercial manufacturing in sepsis, strengthening the production infrastructure needed for future regulatory and commercial milestones.
Field | Content |
Article Type | Deals |
Companies | ABIONYX Pharma; OLON |
Deal Type | Strategic biologics manufacturing partnership |
Key Asset | CER-001 |
Therapy Areas | LCAT deficiency; sepsis |
Technology/Modality | Recombinant apolipoprotein A-I-based HDL-mimetic biologic |
Manufacturing Scope | Integrated manufacturing framework supporting regulatory validation and potential commercial production |
Validation Activities | Two validation batches |
Regulatory Focus | LCAT deficiency regulatory pathway |
Commercial Manufacturing Focus | Potential future commercial production for sepsis |
Financial Terms | Not disclosed in the supplied announcement summary |
What Happened | ABIONYX Pharma and OLON entered a strategic manufacturing partnership to advance production readiness for CER-001. |
Why It Matters | The agreement supports manufacturing validation and regulatory preparation for a specialist biologic while establishing infrastructure for potential commercial supply. |
Supporting Context | CER-001 is a recombinant apoA-I-based HDL-mimetic biologic being developed in LCAT deficiency and sepsis. |
Strategic Rationale | ABIONYX is strengthening CER-001 manufacturing capabilities through OLON's biologics production expertise to support regulatory requirements and future scale-up. |
Potential Impact | The collaboration could improve manufacturing readiness and support future regulatory submissions and commercial supply if development programmes succeed. |
Key Takeaway | ABIONYX and OLON have partnered to support CER-001 validation manufacturing and potential commercial production. |
What to Watch | Completion of validation batches, regulatory progress in LCAT deficiency, sepsis development milestones and commercial manufacturing readiness. |
Primary Source | ABIONYX Pharma |
Relevant Date | 7 October 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Kommentare